Innovative anticancer therapies based on the activation of the immune system offer promise
in the battle against cancers resistant to traditional treatments. Examples of such therapeutic …

Immunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell
death that activates, rather than suppresses, innate and adaptive immune responses. Such …

Most metastatic cancers remain incurable due to the emergence of apoptosis-resistant
clones, fuelled by intratumour heterogeneity and tumour evolution. To improve treatment …

Although the curative effect of hematological malignancies has been improved in recent
years, relapse or drug resistance of hematological malignancies will eventually recur …

Immunogenic cell death (ICD) is a stress-driven form of regulated cell death (RCD) in which
dying tumor cells' specific signaling pathways are activated to release damage-associated …

Immunogenic cell death (ICD) is a form of programmed cell death with a strong sense of
inflammatory detection, whose powerful situational awareness can cause the reactivation of …

Immunotherapy has remarkably revolutionized the management of advanced HCC and
prompted clinical trials, with therapeutic agents being used to selectively target immune cells …

Cancer immunotherapy has been acknowledged as a new paradigm for cancer treatment,
with notable therapeutic effects on certain cancer types. Despite their significant potential …

Incomplete radiofrequency ablation (IRFA) triggers mild protective autophagy in residual
tumor cells and results in an immunosuppressive microenvironment. This accelerates the …

Due to the specific advantages of ultrasound (US) in therapeutic disease treatments, the
unique therapeutic US technology has emerged. In addition to featuring a low‐invasive …